This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: PALLAS

August 2012 Br J Cardiol 2012;19:122–3 doi:10.5837/bjc.2012.020

Translating regulatory advice into practice: use of dronedarone and older anti-arrhythmics in AF management

A consensus position statement. A John Camm, Chris Arden, Anna-Maria Choy, Riyaz A Kaba, David Keane, Khalid Khan, Ernest Lau, Gregory Y H Lip, Francis Murgatroyd, G Andre Ng, Nicholas Peters, Henry Purcell, Peter Stafford, Neil Sulke, Helen Williams

Abstract

Introduction Patients with atrial fibrillation (AF) can benefit from rhythm management to improve unpleasant symptoms or increase exercise capacity,1 making anti-arrhythmic drugs (AADs) an important option in the management of AF. The benefits of any AAD must be weighed against the risks of adverse effects, which in some cases are serious. Defined indications for the use of AADs have been developed by regulatory bodies such as the European Medicines Agency (EMA) and US Food and Drug Administration (FDA), which, in addition to guidelines from groups such as the UK National Institute for Health and Clinical Excellence (NICE) and the European So

| Full text

May 2012

Position statement on anti-arrhythmic drugs

Abstract

Click to read the full article

| Full text

October 2011 Br J Cardiol 2011;18:203

Dronedarone to be restricted

BJCardio Staff

Abstract

The Agency has stated that because of the increased risk of liver, lung, and cardiovascular adverse events, dronedarone, should only be prescribed after alternative treatment options have been considered. It advises that patients currently taking dronedarone should have their treatment reassessed by their physician at their next scheduled visit. Dronedarone is currently approved for the treatment of paroxysmal or persistent atrial fibrillation or atrial flutter. The restriction is based on a review of the PALLAS trial, which was stopped early because of an increased risk of cardiovascular events among patients on dronedarone, as well as other

| Full text
In brief

August 2011 Br J Cardiol 2011;18:156–7

In brief

BJCardio Staff

Abstract

SAPIEN valve positive results Clinicians have achieved successful one-year outcomes in high-risk or inoperable patients undergoing transcatheter aortic valve replacement during the first two years since release of the valve (Sapien®, Edwards) commercially, according to results presented at the Euro PCR 2001 meeting in Paris, France. Despite high predicted mortality and multiple co-morbidities in many of these patients, survival at one year was 76% in the 1,038 patients treated as part of Cohort I (first year of commercialisation), and 77% in the 1,269 patients treated as part of Cohort II (second year of commercialisation).  Since November

| Full text
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now